AI Terminal
BerGenBio
Report Publication Announcement • Feb 3, 2020
3555_rns_2020-02-03_da29541f-8257-46a5-8ea9-844b446b8f20.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
BERGENBIO ASA: Invitation to fourth quarter and full year 2019 results presentation and webcast
Bergen, Norway, 3 February 2020 – BerGenBio ASA (OSE:BGBIO), will announce its results for the fourth quarter and full year 2019 on Tuesday 11 February 2020. A presentation by BerGenBio's senior management team will take place at 10 am CET at:
Hotel Continental Stortingsgaten 24/26 Oslo
The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording will be available shortly after the webcast has finished.
The results report and presentation will be available at www.bergenbio.com in the section: Investors/Financial Reports from 7:00 am CET the same day.
-Ends-
Contacts
Richard Godfrey CEO, BerGenBio ASA +47 917 86 304
Rune Skeie, CFO, BerGenBio ASA [email protected] +47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Nicholas Brown, Lucy Featherstone, Carina Jurs, Consilium Strategic Communications [email protected] +44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers [email protected] +47 995 13 891
About BerGenBio
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia. A first-in-class functional blocking anti-AXL antibody is undergoing Phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify those patient populations most likely to benefit from bemcentinib: this is expected to
facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com